收稿日期: 2023-12-26
网络出版日期: 2024-06-13
基金资助
江苏省卫生健康委科研项目(M2022015);苏州市科技计划项目(SKY2023048);苏州市医学重点扶持学科项目(SZFCXK202111)
The clinical symptoms, quality of life and laboratory indexes of newly diagnosed chronic obstructive pulmonary disease with hypertension
Received date: 2023-12-26
Online published: 2024-06-13
目的 探讨初诊慢性阻塞性肺疾病(COPD)伴高血压患者呼吸道症状、生存质量、血常规及外周血骨代谢指标特征及意义。 方法 选取2019年1月至2022年4月在我院治疗的初诊COPD伴高血压患者92例作为观察组,同时选取初诊无高血压的COPD患者92例作为对照组,比较两组改良版英国医学研究委员会呼吸问卷(mMRC)、COPD患者自我评估测试问卷(CAT)、COPD全球倡议(GOLD)、SF-36量表评分、血常规及骨代谢指标差异。 结果 观察组mMRC评级≥2级的比例、CAT评分明显高于对照组(P < 0.05),而SF-36评分明显低于对照组(P < 0.05)。观察组GOLD分级明显高于对照组(P < 0.05),用力肺活量(FVC)和第一秒呼气量(FEV1)明显低于对照组(P < 0.05)。观察组和对照组白细胞计数(WBC)、中性粒细胞计数(NEUT)、淋巴细胞计数(LYM)等比较差异无统计学意义(P > 0.05);观察组股骨颈骨密度、血钙水平明显低于对照组(P < 0.05),而甲状旁腺激素(PTH)和骨钙素(BGP)水平明显高于对照组(P < 0.05)。观察组C反应蛋白(CRP)、降钙素原(PCT)、白细胞介素(IL)-6、IL-4和IL-10明显高于对照组(P < 0.05)。观察组高血压分级与mMRC评级、CAT评分和GOLD分级呈正相关(rs = 0.455、0.302、0.501,P < 0.05),而与FVC、FEV1呈负相关(rs = -0.311、-0.334,P < 0.05)。 结论 初诊COPD伴高血压病患者呼吸症状较重,生存质量较差,发生骨质疏松风险增加,同时患者血压情况与呼吸症状程度有一定关系。
毛燕青 , 王亚楠 , 李洁 . 初诊慢性阻塞性肺疾病伴高压病临床症状、生存质量及实验室指标研究[J]. 实用医学杂志, 2024 , 40(11) : 1549 -1553 . DOI: 10.3969/j.issn.1006-5725.2024.11.014
Objective We tried to investigate the difference of respiratory symptoms, quality of life, blood routine examination and bone metabolism in patients with newly diagnosed chronic obstructive pulmonary disease with and without hypertension. Methods A total of 92 newly diagnosed patients with chronic obstructive pulmonary disease and hypertension treated in our hospital from January 2019 to April 2022 were selected as the observation group, and 92 newly diagnosed patients with COPD without hypertension were selected as the control group. The modified British Medical Research Council Respiratory Questionnaire (mMRC), Chronic Obstructive Pulmonary Disease Self Assessment Test Questionnaire (CAT), Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD), SF-36 scale scores, blood routine examination and bone metabolism indexes were different. Results The rate of mMRC grade ≥ 2 and CAT score of the observation group were significantly higher than those of the control group (P < 0.05), while the SF-36 score was significantly lower than that of the control group (P < 0.05). The GOLD grading of the observation group was significantly higher than that of the control group (P < 0.05). The forced vital capacity (FVC) and the first second expiratory volume (FEV1) in the observation group were significantly lower than those in the control group (P < 0.05). There was no significant difference between the observation group and the control group in white blood cell count (WBC), neutrophil count (NEUT) and lymphocyte count (LYM) etc (P > 0.05). The bone mineral density of the femoral neck and blood calcium in the observation group were significantly lower than those in the control group (P < 0.05), while the parathyroid hormone (PTH) and osteocalcin (BGP) were significantly higher than those in the control group (P < 0.05). The levels of C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), IL-4, and IL-10 in the observation group were significantly higher than those in the control group (P < 0.05). The hypertension grade in the observation group was positively correlated with mMRC grade, CAT score and GOLD grade (rs = 0.455, 0.302 and 0.501, P < 0.05), but negatively correlated with FVC and FEV1 (rs = -0.311 and -0.334, P < 0.05). Conclusion The newly diagnosed patients with chronic obstructive pulmonary disease and hypertension have severe respiratory symptoms, poor quality of life, and an increased risk of osteoporosis, and the patient's blood pressure is related to the degree of respiratory symptoms.
| 1 | CHRISTENSON S A, SMITH B M, BAFADHEL M, et al. Chronic obstructive pulmonary disease[J]. Lancet,2022,399(10342):2227-2242. doi:10.1016/s0140-6736(22)00470-6 |
| 2 | YANG I A, JENKINS C R, SALVI S S. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment[J]. Lancet Respir Med,2022,10(5):497-511. doi:10.1016/s2213-2600(21)00506-3 |
| 3 | CíFKOVá R. Hypertension in Pregnancy: A Diagnostic and Therapeutic Overview[J]. High Blood Press Cardiovasc Prev,2023,30(4):289-303. doi:10.1007/s40292-023-00582-5 |
| 4 | HIDAYAT A A, GUNAWAN V A, IRAGAMA F R, et al. Risk Factors and Clinical Characteristics of Acute Kidney Injury in Patients with COVID-19: A Systematic Review and Meta-Analysis[J]. Pathophysiology,2023,30(2):233-247. doi:10.3390/pathophysiology30020020 |
| 5 | GREULICH T, WEIST B J D, KOCZULLA A R, et al. Prevalence of comorbidities in COPD patients by disease severity in a German population[J]. Respir Med, 2017,132:132-138. doi:10.1016/j.rmed.2017.10.007 |
| 6 | WANG M T, LIOU J T, LIN C W, et al. Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study[J]. JAMA Intern Med, 2018,178(2):229-238. doi:10.1001/jamainternmed.2017.7720 |
| 7 | 梁振宇, 陈荣昌. 慢性阻塞性肺疾病诊疗指南(2021年修订版)修订历程及思考[J]. 中华结核和呼吸杂志, 2021,44(3):165-166. doi:10.3760/cma.j.cn112147-20210207-00098 |
| 8 | 于超,王英杰,迟相林,等. 2018年版欧洲动脉高血压管理指南与中国高血压防治指南在高血压定义、分类与分层上的几点异同[J]. 中华高血压杂志, 2019,27(9):811-813. |
| 9 | 范艺龄, 苗青, 廖星,等. 六君子汤联合西医疗法治疗慢性阻塞性肺疾病稳定期的有效性和安全性随机对照试验的系统评价和Meta分析[J]. 中国中药杂志, 2020,45(22):5331-5343. |
| 10 | 谭漫琳,简文星,梁秋菊,等. 不同评价系统对慢阻肺患者病情及治疗疗效的评估价值[J]. 南方医科大学学报, 2021,41(7):1119-1124. doi:10.12122/j.issn.1673-4254.2021.07.23 |
| 11 | 崔亚楠,陈平,陈燕. 2018年版慢性阻塞性肺疾病全球倡议诊断及处理和预防策略解读[J]. 中华结核和呼吸杂志, 2018,41(3):236-239. doi:10.3760/cma.j.issn.1001-0939.2018.03.019 |
| 12 | JOELSON A, SIGMUNDSSON F G, KARLSSON J. Responsiveness of the SF-36 general health domain: observations from 14883 spine surgery procedures[J]. Qual Life Res, 2022,31(2):589-596. doi:10.1007/s11136-021-02913-2 |
| 13 | 范晓琳,杨小华,刘月军,等. 2型糖尿病性骨质疏松患者骨小梁分数与骨代谢标志物的相关性分析[J]. 中国骨质疏松杂志, 2021,27(11):1599-1602,1613. doi:10.3969/j.issn.1006-7108.2021.11.008 |
| 14 | 秦川, 艾芬, 付晓幸. 中老年高血压患者使用培哚普利治疗3年对骨密度及骨代谢指标的影响[J]. 中国骨质疏松杂志,2020,26(3):390-393. doi:10.3969/j.issn.1006-7108.2020.03.017 |
| 15 | 徐凤周, 范金鹏, 高开茜,等. 维生素K2联合咪达普利对合并高血压的老年女性骨质疏松患者的疗效观察[J]. 中国骨质疏松杂志, 2021,27(2):269-274. doi:10.3969/j.issn.1006-7108.2021.02.023 |
| 16 | 吴雅琳, 翟建, 胡琴,等. 定量CT骨密度测量应用于血压与腰椎骨密度相关性的研究[J]. 临床放射学杂志, 2020,39(2):382-385. |
| 17 | 祝凯,李娜,彭朋. 吸气肌耐力训练对高血压患者肺功能、呼吸肌力量及运动能力的影响[J]. 中华物理医学与康复杂志,2021,43(8):707-711. doi:10.3760/cma.j.issn.0254-1424.2021.08.009 |
| 18 | OLSSON K M, CORTE T J, KAMP J C,et al. Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management[J]. Lancet Respir Med, 2023,11(9):820-835. doi:10.1016/s2213-2600(23)00259-x |
| 19 | 陈凌辉,刘宗军,郜俊清,等. 运动康复对PCI术后患者心肺功能和预后的影响[J]. 临床心血管病杂志, 2022,38(7):577-581. |
| 20 | 孙以成,林玉芳. 骨愈灵胶囊对绝经后骨质疏松症的疗效及骨代谢指标的影响[J]. 中国骨质疏松杂志, 2020,26(3):416-418,424. doi:10.3969/j.issn.1006-7108.2020.03.023 |
| 21 | SHOSHTARI F S, BIRANVAND S, REZAEI L, et al. The impact of hemodialysis on retinal and choroidal thickness in patients with chronic renal failure[J]. Int Ophthalmol, 2021,41(5):1763-1771. doi:10.1007/s10792-021-01735-y |
| 22 | 张炳坤,张喜善. 骨代谢标志物在骨质疏松症诊治中的应用[J]. 中国矫形外科杂志, 2022,30(16):1483-1486. |
| 23 | 吴春娃,李凯,张翠翠,等. CRP与PCT和SAA对恶性肿瘤化疗后细菌性感染的诊断价值[J]. 中华医院感染学杂志, 2021,31(3):355-359. |
| 24 | GUL B, ANWAR R, SALEEM M,et al. Cassia absus-mediated upregulation of IL-4, IL-10 and downregulation of IL-1β, IL-6, TNF- α, NF-κB, IFN-γ in CFA-induced arthritis model[J]. Inflammopharmacology, 2023,31(3):1241-1256. doi:10.1007/s10787-023-01185-1 |
| 25 | 王龙龙,张明,许淑娣,等. COPD患者脑微出血发病率[J]. 中国老年学杂志, 2023,43(5):1074-1077. doi:10.3969/j.issn.1005-9202.2023.05.015 |
/
| 〈 |
|
〉 |